Condition: TNBC, Triple Negative Breast Cancer · Sponsor: Fudan University
This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
This description comes directly from the study's public registry record.
Wang Hongxia · 021-64175590 · whx365@126.com
Tao Zhonghua · 13774315805 · drtaozhh@126.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06786026